Clare I. Hobbs
GlaxoSmithKline (United Kingdom)(GB)Age UK(GB)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Computational Drug Discovery Methods, RNA and protein synthesis mechanisms, Chemical Synthesis and Analysis, Ubiquitin and proteasome pathways
Most-Cited Works
- → 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain(2014)89 cited
- → Discovery, SAR, and X-ray Binding Mode Study of BCATm Inhibitors from a Novel DNA-Encoded Library(2015)83 cited
- → GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain(2016)65 cited
- → Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor(2011)54 cited
- → Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase(2017)46 cited
- → Discovery and Optimization of Potent, Selective, and in Vivo Efficacious 2-Aryl Benzimidazole BCATm Inhibitors(2016)44 cited
- → The Discovery of in Vivo Active Mitochondrial Branched-Chain Aminotransferase (BCATm) Inhibitors by Hybridizing Fragment and HTS Hits(2015)42 cited
- → Crystal structures of ASK1‐inhibtor complexes provide a platform for structure‐based drug design(2013)28 cited
- → Kinetic assay for characterization of spleen tyrosine kinase activity and inhibition with recombinant kinase and crude cell lysates(2008)17 cited
- → Tipping points in open systems: bifurcation, noise-included and rate-dependent examples in the climate system(2013)6 cited